Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors-Reference-Cited by-同舟云学术

Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors

Published:2010-12 Issue:3 Volume:119 Page:457-461
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Emons Günter,Kaufmann Manfred,Gorchev Grigor,Tsekova Valentina,Gründker Carsten,Günthert Andreas R.,Hanker Lars C.,Velikova Maya,Sindermann Herbert,Engel Jürgen,Schally Andrew V.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference17 articles.

1. An overview of targeted treatments in cancer;Abou-Jawde;Clin Ther,2003

2. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancer;Emons;Hum Reprod,1994

3. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500–1000 times more potent;Nagy;Proc Natl Acad Sci USA,1996

4. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations;Buchholz;Proc Natl Acad Sci USA,2006

5. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors;Schally;Eur J Endocrinol,1999

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D‐Cys6‐LHRH vedotin, against ovarian cancer cell lines;Chemical Biology & Drug Design;2024-04

2. Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease;Journal of Clinical Medicine;2023-10-27

3. Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer;International Journal of Molecular Sciences;2023-10-16

4. An LHRH peptide-conjugated ruthenium(II) complex as tumor-targeted theranostic anticancer agent;Inorganic Chemistry Communications;2022-02

5. New drug delivery strategies targeting the GnRH receptor in breast and other cancers;Endocrine-Related Cancer;2021-11-01